Figure 4.
Donor-specific MLR and CML unresponsiveness in Patients 2, 4, and 5 is not dependent on CD25+ T cells. (A) Pre-transplant and POD 182 whole PBMC, T cells and CD25− fractions in Patient 2, pre-transplant and POD 912 whole PBMC, T cells and CD25− fractions in Patient 4, pre-transplant and POD 275 whole PBMC and CD25− fractions in Patient 5 were tested against irradiated donor and third party stimulators in MLR; (B) POD 182 whole PBMC and CD25− fraction in Patient 2, POD 540 whole PBMC and CD25− fraction in Patient 4, pre-transplant and POD 275 whole PBMC and CD25− fraction in Patient 5 were stimulated for 5 days with irradiated PBMC, then tested at different ratios for cytotoxicity against donor and third party targets in CML assays.